Page last updated: 2024-10-28

miltefosine and Immune System Diseases

miltefosine has been researched along with Immune System Diseases in 1 studies

miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.

Immune System Diseases: Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.

Research Excerpts

ExcerptRelevanceReference
"Oral treatment with miltefosine is generally well tolerated and has relatively few adverse effects."1.40Repurposing miltefosine for the treatment of immune-mediated disease? ( Hommes, DW; Peppelenbosch, MP; van den Brink, GR; Verhaar, AP; Wildenberg, ME, 2014)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Verhaar, AP1
Wildenberg, ME1
Peppelenbosch, MP1
Hommes, DW1
van den Brink, GR1

Other Studies

1 other study available for miltefosine and Immune System Diseases

ArticleYear
Repurposing miltefosine for the treatment of immune-mediated disease?
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 350, Issue:2

    Topics: Adaptive Immunity; Adjuvants, Immunologic; Drug Discovery; Humans; Immune System Diseases; Immunity,

2014
chemdatabank.com